Provention Bio, a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, secured a term loan facility of up to $125 million with Hercules Capital.
Alladapt Immunotherapeutics, a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, entered into a term loan agreement for up to $50 million with Hercules Capital.
atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, entered into a term loan facility for up to $175 million with Hercules Capital.
Gritstone bio, a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, entered into an $80 million credit facility with Hercules Capital and Silicon Valley Bank.
Hercules Capital increased its existing credit facilities with MUFG Bank and Sumitomo Mitsui Banking Corporation from a combined $500 million to $720 million, subject to a borrowing base, leverage and other restrictions.
Viridian Therapeutics, a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, entered into a debt financing agreement with Hercules Capital for up to $75 million.
Hercules Capital amended TG Therapeutics’ existing term loan facility agreement to increase the size of the facility to $200 million, with $70 million funded at closing.
Hercules Capital has originated more than $2 billion year to date in annual total gross debt and equity commitments, breaking its previous one-year record of $1.47 billion.
Hercules Capital, a specialty financing provider to companies backed by venture capital and select private equity firms, entered into a $100 million multi-currency credit facility with Sumitomo Mitsui Banking Corporation.
Locus Biosciences, a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for bacterial and inflammatory diseases, entered a credit facility of up to $25 million with Hercules Capital.